Pane wikiwiki
Analyze Bachem’s financial snapshot, H1 2026 CapEx, and SIX insider trades to build a peptide CDMO supplier risk score and contingency playbook.
ʻO ka wehe ʻana i ka ʻikepili kālā a Bachem: Nā Enekinia Ulu vs. ʻO ka hoʻopiʻi CapEx
ʻO ka hoʻomaopopo ʻana i ke ala kālā o kahi peptide CDMO mua e pono ai ka nānā ʻana i ka pilina ma waena o ka loaʻa kālā, hoʻokomo kālā, a me ka pono hana.
FY 2025 Top-Line Growth (+19.2% Local Currency)
│
├──> CMC Development Segment Expansion (+39.5% Local Currency in H1 2026)
│
└──> Heavy CapEx Acceleration (CHF 148.4M in H1 2026; ~45% of Sales)
│
└──> Temporary Margin Compression (EBITDA Margin down to 25.4%)
Top-Line Trajectory a me ka CMC Development Surge
I kona FY 2025 hōʻike, Ua hōʻike ʻo Bachem i nā kūʻai pūʻulu o CHF 695.1 miliona—he hoʻonui makahiki o ka makahiki 14.8% ma Swiss francs a 19.2% i loko o nā kālā kūloko—i hui pū ʻia me kahi palena EBITDA ikaika hou o 30.9% (CHF 214.7 miliona). Ke hoʻomau nei i kēia hoʻonui i ka hapa mua o 2026, kūʻai aku i CHF 326.4 miliona (+7.3% ma nā kālā kūloko).

ʻO ka hōʻailona hana koʻikoʻi i loko ʻO ka H1 o Bachem 2026 hōʻike kālā ʻo ia ka ulu like ʻole o kāna Kemika, Hana ʻana, a me na Mana (CMC) ʻoihana hoʻomohala. Ua hoʻonui ʻia ke kūʻai aku ʻana o CMC Development 35.4% ma Swiss francs (39.5% ma nā kālā kūloko) e hiki aku i CHF 167.5 miliona ma ka H1 2026. ʻO kēia piʻi wikiwiki e hōʻike ana i ʻelua mau ʻano ʻoihana kumu:
-
Hoonui Paipu: Nā moho peptide pae maʻi (mai ka nānā ʻana i ka pae mua ma o nā haʻawina hoʻonaʻauao IND a me ka Phase 3 na hoao ana) ke komo nei i ka hoʻomohala ma nā puke mōʻaukala.
-
Hoʻohuihui Peptide Paʻakikī ʻenehana: Hoʻonui nui nā moho lāʻau o kēia wā i nā hoʻololi paʻakikī—e like me nā paʻa disulfide lehulehu, lipophilic fatty acid conjugation, kemika covalent dynamic, a me nā ʻakika amino non-canonical—e koi ana i ka loea synthetic kūikawā.
Mechanics Dilution Margin: Hoʻonui ʻo CapEx a me Ramp-Up Drag
ʻOiai e mau ana ka ikaika o ka noi kiʻekiʻe, Hōʻike nā anana waiwai i ke kumukūʻai hana o ka scaling wikiwiki. I ka H1 2026, ʻO ka palena EBITDA o Bachem i hoʻopaʻa ʻia e kahi 370 kumu kumu makahiki-i-makahiki i 25.4% (CHF 82.8 miliona).
Hoʻopili pololei ʻia kēia dilution margin i kahi hoʻolaha hoʻolimalima kālā koʻikoʻi. Ua hoʻolilo ʻo Bachem iā CHF 332.6 miliona ma CapEx i ka wā FY 2025 a he CHF hou aku 148.4 miliona ma ka H1 2026 hoʻokahi wale nō - e hōʻike ana i kahi ʻano 45% o ka huina loaa o ka hapa mua. makahiki piha 2026 Ke hoʻomau nei nā kuhi CapEx ma waena o CHF 350 miliona a me CHF 400 miliona.
No nā mea kūʻai biopharma, ʻO kēia kiʻekiʻe CapEx-i-loaʻa ratio hoʻopuka i kahi hōʻailona hana ʻelua:
Ki Takeaway: Hōʻike ʻo High CapEx reinvestment i ka hoʻokō lōʻihi i ka mana hana peptide honua. Eia naʻe, i ka wā o ka hoʻokō kino ʻana o ka peptide synthesis paʻa paʻa hou (SPSS) hale kūkulu hale, nā lumi hoʻomaʻemaʻe, a me nā kaʻaahi hoʻomaʻemaʻe ʻakomi, ʻO ka ʻike CDMO i hoʻokiʻekiʻe ʻia ma luna, kauo depreciation, a me nā hemahema o nā limahana mua e hiki ai ke hoʻopaʻa i ka wikiwiki o ka hana a me ka loaʻa ʻana o ka slot.
ʻO Sisslerfeld's CHF 500M+ hoʻohiki: Hoʻolālā Hoʻolālā Palekana vs. Laka-Ma loko
Loaʻa i ka papahana hoʻopukapuka makahiki ʻo Bachem kahi hoʻokō hoʻolālā lōʻihi ma mua o CHF 500 miliona e kūkulu i kahi hale hana nui ma Sisslerfeld, Kuikilana, kākoʻo ʻia e nā ʻaelike hoʻolako kalepa nui e hoʻonui ana ma waho 2030.
ʻOiai ke kūkulu nei ka mega-facility i ka hiki no ka wā lōʻihi no nā blockbusters pāʻoihana, hoʻopaʻa pū lākou i nā waiwai hana i loko o nā ʻōnaehana lōʻihi. No nā mea hoʻomohala biopharma waena a me nā hui noiʻi e pono ai ka 100g a 10kg mau pūʻulu no nā hoʻokolohua lapaʻau., ʻO ka nui-1 mega-facilities e hoʻokaʻawale i nā ʻāpana kalepa he mau haneli mau kilo, e hoʻonui ana i nā paepae puke slot no nā polokalamu liʻiliʻi.
Ka wehewehe ʻana i ka hana kālepa Insider a me nā hōʻailona hoʻokele hoʻokele
Ma waho aʻe o nā hōʻike kālā kiʻekiʻe, Hāʻawi ka nānā ʻana i ke kālepa insider i ka ʻike qualitative waiwai i ka manaʻo hoʻokele, hooponopono hui, a me ka hilinaʻi hoʻokō.
|
Lā |
Ke kuleana o loko |
ʻAno Kūʻai |
Mahele i komo |
Kūlana Kūlana & Hoailona hana |
|---|---|---|---|---|
|
Malaki 17, 2026 |
Luna Hooko ole |
Makeke Kūʻai |
+248 Māhele |
ʻO ka alignment kapikala pilikino maʻalahi e kākoʻo ana i ka thesis hoʻonui lōʻihi. |
|
Mei 8, 2026 |
Luna Hooko |
Kuai Makeke Wehe |
-1,373 Māhele |
ʻO ka hoʻihoʻi hou ʻana i ka waihona pilikino pilikino (~0.0018% o ka huina kuai); ʻaʻohe puka kula. |
Eono Hooia Hoike: ʻO ka Mei 2026 Kuai Hooko vs. Maraki Luna Hooko kuai
Wahi a ʻEono mau moʻolelo kūʻai kūloko o Swiss Exchange, Ua noho haʻahaʻa ka hana insider ma Bachem e pili ana i ka huina kālā o ka mākeke. Nā hanana nui i ka wā mua 2026 ua komo pū me kahi kūʻai ʻana o ka luna hoʻokō ʻole (+248 mahele) i ka waena o Malaki, ukali ʻia e kekahi luna hoʻokō kūʻai mahele (-1,373 mahele ma CHF 81.02) i ka mua o Mei.
Hoʻohālikelike hou vs. Hae Ulaula: Ka wehewehe ʻana i ka hōʻailona hoʻomalu
I ka loiloi ʻana i nā kālepa hoʻokō me nā pōʻai CapEx nui, Pono nā hui kūʻai a me nā hui kālā e hoʻokaʻawale ma waena o ka hoʻoponopono hou ʻana i ke kaulike maʻamau a me nā hae ʻulaʻula:
-
Hōʻikeʻike Hae ʻulaʻula: Kūleʻa, ka hoʻokuʻu ʻana i nā hana lehulehu ma mua o ka hoʻoponopono ʻana i ka palena, hoʻopaneʻe hale, a i ʻole ke ʻano hoʻoponopono 483 hoopuka ana.
-
Hana Hana maʻamau: Hoʻokaʻawale ʻia nā hana hoʻokō i ka liʻiliʻi ma mua o 0.01% o ka pōʻai makeke i ka wā o ka hoʻokō ʻana o ka hale hana.
Kūlike nā moʻolelo o loko o Bachem me ke ʻano hana maʻamau. ʻO ke kūʻai hoʻokō e hōʻike ana i ka hoʻokele waiwai pilikino maʻamau ma mua o ka hopohopo i loko e pili ana i ka hiki ʻana o ka ʻenehana a i ʻole ka mea kūʻai aku.. Eia naʻe, ʻike maopopo ʻia ka haʻawina ākea no ka kūʻai ʻana i ka biopharma: Hāʻawi ka nānā ʻana i nā kālepa hoʻokō i kahi ʻano ʻōlelo aʻoaʻo koʻikoʻi i ka wā e loiloi ai i ka paʻa kālā o ka mea hoʻolako CDMO mua.
Nā hōʻailona Macro no ka ʻĀina ʻĀina CDMO Peptide Nui
ʻO ka hoʻohui ʻana i ka paʻi kālā a me ka ʻike insider e hōʻike ana i ka hoʻololi ʻana o ke kūkulu ʻana ma waena o ke kaiaola hana ʻaelike..
ʻAno Makro 1: Kalepa Slot Crowd-Ma waho
↳ Hoʻopaʻa nā ʻaelike Mega-GLP-1 i nā reactor SPPS nui, ke koi nei i ka clinical R&D i nā pila lua.
ʻAno Makro 2: ʻO ka CapEx-to-Revenue Lead-Time Lag
↳ Pono ka hoʻolilo kālā nui he 18-36 mahina ma mua o ka hōʻoia ʻia ʻana, hoʻokolo-mākaukau GMP lumi maʻemaʻe puka.
ʻAno Makro 3: Pono no Agile Dual-Sourcing
↳ Pono nā mea hoʻomohala Biopharma e hoʻohui i nā heleuma kālepa tier-1 me ka nimble, nā CDMO kūikawā hoʻomaʻemaʻe kiʻekiʻe.
ʻO nā Bottlenecks Hiki i ka Tier-1: ʻO nā ʻaelike Mega-Kalepa e hoʻopio nei i ka Clinical R&ʻO D
E like me ke koi kalepa no ka metabolic, oncology, a me ka piʻi ʻana o nā peptides diagnostic, Ke hāʻawi nei nā CDMO tier-1 i nā waiwai synthetic koʻikoʻi i nā ʻaelike hoʻolako lōʻihi-haneri-kilogram. No laila, nā papahana hoʻolālā kino (Māhele 1–3) a me R&Hiki ke hoʻokuʻu ʻia nā kaʻina D i nā puka makani hoʻonohonoho lua a i ʻole ke alo ʻana i ka nui o nā kauoha liʻiliʻi. (MOQ) nā hoʻopaʻi.
ʻO ka CapEx-to-Revenue Disconnect: Hoʻokumu ʻia ʻo Capacity Buildout vs. Loaʻa i ka Slot Manawa maoli
ʻO ka manaʻo kuhihewa maʻamau i waena o nā hui kūʻai e manaʻo nei ua unuhi ʻia ka waihona kālā CapEx i hoʻolaha ʻia e CDMO i ka hiki ke pae pae koke.. I ka ʻoiaʻiʻo, ke kukulu ana i Papa 100 hale lumi hoʻomaʻemaʻe, hoʻokomo ʻana i nā reactors solid-phase, hōʻoia ʻana i ka chromatography wai hana kiʻekiʻe (RP-HPLC) ʻōnaehana hoʻomaʻemaʻe, a me ka hoʻopaʻa ʻana i ka ʻae ʻia ʻana o ke kaiapuni a me ka sterility e hana i kahi lag 18-a-36-mahina..
I loko o kēia puka makani kūkulu, piʻi aʻe ka pilikia o ka mea hoʻolako ma muli o ka hoʻopaneʻe ʻana o ka lako hana, analytical method transfer bottlenecks, a me nā koi hoʻolimalima limahana akamai.
ʻO kahi Pragmatic Supplier Risk Scoring Framework for Biopharma Procurement & R&ʻO D
E hoʻololi i ka ʻikepili kālā lehulehu, EONO nā waiho ʻana o loko, a me nā hōʻailona hana i nā helu mea kūʻai, Hiki i nā hui kūʻai biopharma a me ka hōʻoia maikaʻi ke kau i kahi kūlana maʻamau 4-ʻO Pillar Peptide CDMO Mea Mea Hoʻolako Pilikia Score Matrix.
|
ʻO ke kia pōʻino |
Kaumaha |
Nā Anana Kūlana Kiʻi |
Nā paepae pilikia (ʻōmaʻomaʻo / Melemele / ʻulaʻula) |
|---|---|---|---|
|
1. Paʻa Waiwai & Ola Kapitala |
30% |
• ʻO CapEx-to-Revenue Ratio• Hoʻihoʻi hou ʻia EBITDA Margin• ʻAiʻai Net / Ke Kaʻa kālā |
ʻōmaʻomaʻo: NA HANA >25%, CapEx/Kuai 15–30% Melemele: UKU 18–24%, CapEx/Kuai >40%ʻulaʻula: NA HANA <15%, kahe kālā maikaʻi ʻole |
|
2. Ka hoʻokaʻawale ʻana & Loaʻa ka Slot |
25% |
• Kalepa vs. R&D Pipeline Mix• Average Tech Transfer Lead Time• Guaranteed Slot Lead-Time Window |
ʻōmaʻomaʻo: Hoʻololi ʻenehana <12 wks, nā kau <8 wksYellow: Hoʻololi ʻenehana 12-20 wiki, nā puka 8–16 wiki ʻulaʻula: Hoʻololi ʻenehana >20 wks, nā kau >20 wks |
|
3. ʻAno maikaʻi, ʻO ka maʻemaʻe & ʻO nā Peptides Synthetic Analytical Rigor |
30% |
• Papa Keena Ma'ema'e Kaiapuni• Laulā ho'ā'o Analytical (HPLC/MS)• Kūʻē SLA (Hoʻololi TFA) |
ʻōmaʻomaʻo: Papa 100 lumi hoʻomaʻemaʻe, piha HPLC/MS/LALYellow: Papa 10,000 lumi hoʻomaʻemaʻe, kumu QARed: lumi hoʻomaʻemaʻe ʻaʻole i hōʻike ʻia, nele i ka ʻikepili MS |
|
4. Aupuni & Ka Manao Loko |
15% |
• Luna Hooko Insider Net Volume• Ke alakaʻi manaʻo nui (PI/CCO) Huli • Moolelo Hooia & Hoʻoponopono Mākaʻikaʻi |
ʻōmaʻomaʻo: Ke alakaʻi kūpaʻa, net neutral/kūʻai tradesYellow: Kūʻai kaʻawale hoʻokō (<0.05% Kāpena)ʻulaʻula: Kūʻai nui C-suite, nā ʻike loiloi |
No ke kōkua: Kia Kaumaha 1 (Ola Ola) a me ka pou 3 (ʻAno maikaʻi & ʻO ka maʻemaʻe) ma 30% kēlā me kēia no nā papahana hoʻomaʻamaʻa. ʻO kahi CDMO i hoʻonui ʻia i ke kālā a i ʻole kahi hale me nā mana endotoxin i hoʻopaʻa ʻia e hoʻoweliweli koke i ka Investigational New Drug (IND) hoʻopaʻa ʻana i nā manawa a me ka palekana hoʻokolohua lapaʻau.
Hoʻolālā Kūʻē & ʻO ka puke pāʻani Multi-Sourcing no Peptide R&D Nā Hui
No ka ho'ēmiʻana i ka pilikia o ka mea hoʻolako, nā alakaʻi kūʻai biopharma a me R&Pono nā alakaʻi D e haʻalele i ka hilinaʻi CDMO hoʻokahi kumu a hoʻopaʻa i kahi papa hana ʻelua-sourcing.
ʻO CDMO Pāʻoihana Papa-1 (e.g., Bachem) Hana ʻia ʻo Peptide
Nānā: Kiʻekiʻe-volo kalepa lako & hoʻopaʻa pāʻoihana hope loa
Pilikia: Laka-i loko, manawa alakai loihi, hoʻololi pūʻulu paʻa
ʻOihana Agile Secondary CDMO (e.g., MOL Changes)
Nānā: Hoʻolālā kaʻina hana maʻamau, FTE/FFS R&ʻO D, hoʻonui i ka mg-a-kg
Pōmaikaʻi: Papa 100 nā lumi hoʻomaʻemaʻe sterile, komo wikiwiki, piha piha HPLC/MS
Hoʻolālā Papalua-Sourcing: Ke hoʻopaʻa nei i nā puke kalepa ʻoiai ʻo Hedging R&D Kau
Ke hilinaʻi nei kahi kaulahao hoʻolako kūpaʻa i kahi hoʻolālā ala ʻelua:
-
Mea hoʻolako heleuma Tier-1: E hoʻohana i nā CDMO honua i hoʻokumu ʻia no ka hana pāʻoihana he mau haneli kiloki kahi e ʻae ʻia ai ka laka paʻa ʻana no ka wā lōʻihi..
-
Hoa Makahiki Agile: E hui pū me kahi maʻalahi, CDMO pili i ka ʻenehana—e like me kahi mea kūikawā ʻO ka peptide synthesis maʻamau a me ka pae hoʻonui—e hoʻoponopono i ka hoʻonohonoho mua ʻana, wikiwiki R&D hoʻomau hou, pilot scale-up, a me ka hoʻopaʻa ʻana i nā pūʻulu lapaʻau.
ʻO nā hoa hana Agile CDMO kūpono: ʻenehana & Nā Koina Hana
I ka hoʻokō 'ana i ke kula kiʻekiʻe, ʻO ka hoa CDMO agile e pale aku i ka paʻa paʻa o ka tier-1, pono e hōʻoia nā hui kemika e kūʻai a me ke kaʻina hana ʻehā mau pae ʻenehana koʻikoʻi:
-
lumi hoʻomaʻemaʻe & Nā Mana Aseptic: E hōʻoia i kēlā synthesis, ka hoomaemae ana, a hiki i ka lyophilization i loko o ka Papa i hōʻoia ʻia 100 nā wahi lumi hoʻomaʻemaʻe ultra-sterile. Mālama kēia i ka hoʻohaumia ʻana i nā ʻāpana a mālama i nā pae endotoxin haʻahaʻa (<0.5 EU/mg) pono no ka ho'āʻo cellular a me nā haʻawina preclinical in vivo.
-
ʻO ke ʻano hana like ʻole: E hōʻoia i ka mākaukau ma nā ala synthetic he nui, me ka Solid-Phase Peptide Synthesis (SPSS), ʻO ka wai-Phase Peptide Synthesis (LPPS), hoʻopaʻa ʻāpana ʻāpana hybrid, a me ka fermentation microbial. Loaʻa i kahi koho ākea o nā hoʻololi pūʻulu hana (pau 300 nā ʻano hoʻololi i loaʻa) hōʻoia i ka hiki ke kaʻina hana paʻakikī.
-
Paʻaʻikepili Analytical: Koi i ka piha, ka palapala hōʻoia o ka ʻikepili kikoʻī (KoA) nā palapala i kākoʻo ʻia e ka spectrometry lehulehu ākea (HRMS) a me ka analytical RP-HPLC chromatograms, me ka quantitative trifluoroacetic acid (TFA) hōʻoia hoʻololi kūʻē.
-
Nā Hoʻohālike lawelawe Agile: E ʻimi i nā mea hoʻolako e hāʻawi ana i nā mea like ʻelua (FTE) a me ka uku no ka lawelawe (FFS) nā hale hana like ʻole e hiki ai ke hoʻonui ʻia mai ka milligram-scale R&D ka nānā ʻana i ka hana hoʻokele multi-kilogram ma o Nā lawelawe peptide CRO a me CDMO.
⚠️ ʻŌlelo Aʻo: Mai ʻae i ka palapala CoA mea kūʻai aku e hilinaʻi wale ana i nā pākēneka maʻemaʻe o UV me ka ʻole o ka hoʻohālikelike ʻana i ka ʻike kikoʻī nui a me nā metric content counterion TFA.. Hiki ke hoʻololi i ka solubility peptide nā counterions i wehe ʻole ʻia a i ʻole nā mea hoʻoheheʻe organik koena, hana olaola, a me ka ʻike cytotoxicity i nā haʻawina holoholona o lalo.
Ma ka hoʻokō agile peptide CDMO multi-sourcing a me ka pale ʻana i ka pilikia, pale nā hui biopharma i kā lākou mau manawa hoʻomohala lāʻau mai nā bottlenecks hiki ke kumu hoʻokahi.
Nā Kūʻai Kūʻai Kūʻai Kūʻai a me ka Hoʻolālā Hana
Hāʻawi nā hōʻike kālā a me nā hana kālepa insider ma nā CDMO alakaʻi i ka mākeke i nā hōʻailona koʻikoʻi nui e pili ana i nā kaohi o ka ʻoihana ākea.. Pono nā mea hoʻoholo ʻo Biopharma e hoʻololi i kēia mau ʻike mākeke i loko o nā pale kaulahao proactive.
Ka papa inoa o nā hana hoʻokō no ka Peptide R&ʻO D & Nā Luna Kūʻai
-
Hoʻoponopono i ka hōʻike CDMO i kēia manawa: E loiloi i ka manaʻo hoʻolako kumu ma waena o nā pipeline peptide ikaika a ʻike i nā hilinaʻi kumu hoʻokahi.
-
E noi i ka 4-Pillar Risk Matrix: E helu i nā helu pōʻino o ka mea hoʻolako no nā mea kūʻai CDMO ikaika a pau me ka hoʻohana ʻana i ka ʻikepili helu kaulike lehulehu, Nā alahele CapEx, a me nā anana manawa alakaʻi.
-
E hoʻokumu i nā hoʻopaʻa inoa lua: Pono i kahi CDMO peptide kūikawā i lako me Papa 100 ʻO ka hui ʻana o ka lumi maʻemaʻe a me nā keʻena analytical sterile no ka hoʻopaʻa ʻana i nā slot hana hana lapaʻau wikiwiki.
-
Hoʻohālikelike i nā SLA Analytical: E hoʻokō i nā koi aelike no ka HPLC pae piha piha, HRMS, a me ka hōʻike maʻiʻo counterion e pili ana i nā kauoha peptide maʻamau.
E hoʻonui i kāu kaulahao lako Peptide me nā hoʻololi MOL
Inā ʻoe e hoʻonui ana i kahi kaʻina hoʻololi paʻakikī mai R&ʻO ka nānā ʻana i ka hana pilote a i ʻole ka hoʻokumu ʻana i kahi pā kumu ʻelua e kūʻē i nā bottlenecks kaha tier-1, MOL Changes hāʻawi i ka peptide synthesis maʻemaʻe kiʻekiʻe i kākoʻo ʻia e ka Papa 100 kaiapuni lumi maemae, koʻikoʻi analytical QC, a me nā hiʻohiʻona hui like FTE/FFS agile.
